{"id":"NCT00709956","sponsor":"Actelion","briefTitle":"Iloprost Power 15 in Pulmonary Arterial Hypertension","officialTitle":"A Multicenter, Double-blind, Randomized, Placebo-controlled, Crossover Study to Assess the Effects of a Single Dose of Iloprost Power 15 on Exercise Capacity in Patients With Symptomatic Pulmonary Arterial Hypertension","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2008-07","primaryCompletion":"2009-08","completion":"2009-08","firstPosted":"2008-07-03","resultsPosted":"2012-10-26","lastUpdate":"2025-02-04"},"enrollment":64,"design":{"allocation":"RANDOMIZED","model":"CROSSOVER","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Pulmonary Arterial Hypertension"],"interventions":[{"type":"DRUG","name":"iloprost (5 µg)","otherNames":["Ventavis(R)"]},{"type":"DRUG","name":"placebo","otherNames":[]}],"arms":[{"label":"Active / placebo","type":"EXPERIMENTAL"},{"label":"Placebo / active","type":"PLACEBO_COMPARATOR"}],"summary":"Patients with symptomatic idiopathic pulmonary arterial hypertension (IPAH), or familial pulmonary arterial hypertension (FPAH) or pulmonary hypertension associated with Human immunodeficiency virus (HIV) or drugs/toxins in New York Heart Association (NYHA) functional class II to IV at baseline, naive to PAH treatment or currently being treated with a stable dose of either bosentan, ambrisentan or sildenafil will be enrolled in the PROWESS 15 study. This randomized, double blind, placebo-controlled, crossover, and single-dose study will determine whether a single inhaled dose of iloprost using the power 15 disc improves exercise capacity compared to placebo in patients with pulmonary arterial hypertension (PAH).","primaryOutcome":{"measure":"6-minute-walk Distance (6MWD)","timeFrame":"Study day 2 or study day 3","effectByArm":[{"arm":"6MWD After Placebo Treatment","deltaMin":330,"sd":22.84},{"arm":"6MWD After Iloprost (5 µg) Treatment","deltaMin":328.6,"sd":55.28}],"pValues":[{"comp":"OG000 vs OG001","p":"0.7883"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":13},"locations":{"siteCount":0,"countries":[]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":31},"commonTop":["Flushing","Cough","Dizziness","Headache","Throat irritation"]}}